India rejects compulsory licence bid for AstraZeneca drug

24-08-2015

India rejects compulsory licence bid for AstraZeneca drug

Vepar5/shutterstock.com

The Indian government has rejected a request by local company Lee Pharma to issue a compulsory licence for AstraZeneca’s diabetes drug Onglyza (saxagliptin).


AstraZeneca, compulsory licence, Indian Patent Office, patent, Onglyza, Lee Pharma, saxagliptin

LSIPR